
Opinion|Videos|March 31, 2025
Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025
A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing significant improvements in mNAPSI 75 and ViSENPsO responses at week 28 compared with placebo, potentially addressing a critical unmet need in psoriasis treatment.
Advertisement
Episodes in this series

Now Playing
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Proactive MG Management Hinges on Better Coverage and Guidelines
2
FDA Expands Sotatercept Indication for PAH
3
Patients, Providers Strongly Favor Oral Therapies in Psoriasis
4
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
5














































